Ticagrelor Versus Prasugrel for the Treatment of Patients with Type 2 Diabetes Mellitus Following Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis

INTRODUCTION: Antiplatelet therapy is very important following percutaneous coronary intervention (PCI). New generation P2Y(12) inhibitors (ticagrelor and prasugrel) might potentially replace clopidogrel for the treatment of post-interventional acute coronary syndrome (ACS). In this analysis, we aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Hua, Tang, Bing, Xu, Chen Hong, Ahmed, Anis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349280/
https://www.ncbi.nlm.nih.gov/pubmed/30456635
http://dx.doi.org/10.1007/s13300-018-0537-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349280/
https://www.ncbi.nlm.nih.gov/pubmed/30456635
http://dx.doi.org/10.1007/s13300-018-0537-7

Ejemplares similares